drugset / Trial / NCT00509834

A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia

NCT00509834

Phase 1/2 Withdrawn AM-Pharma
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a phase-I, double-blind, randomized study with hLF1-11 to study the tolerability and early efficacy of hLF1-11 compared to standard fluconazole therapy in hospitalized patients with invasive Candida infection.

Timeline

Start
2008-07
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject hLF1-11 Peptide 0.5 mg Intravenous
Background Fluconazole Small molecule 1 g Intravenous

Indications